The FDA has granted permission for Revolution Medicines to provide access to its investigational RAS inhibitor, daraxonrasib, through an Expanded Access Program (EAP) for certain patients with metastatic pancreatic ductal […]
The Promise of Personalized Pancreatic Cancer Vaccines
From April 17-22, 2026, the American Association for Cancer Research (AACR) held their annual meeting in San Diego, CA. The AACR Annual Meeting brings together clinicians, researchers, and health-care professionals […]
Researchers Identify Tumor-Suppressing Mechanism in Healthy Pancreas
The American Association for Cancer Research (AACR) held their annual meeting in San Diego, CA from April 17-22, 2026. The AACR Annual Meeting gathers cancer researchers from around the world […]
Unprecedented Results from Revolution Medicines for Patients with Metastatic Pancreatic Cancer
Revolution Medicines announced exciting results on three clinical trials evaluating daraxonrasib, their oral RAS inhibitor, that have the potential to transform treatment options for patients with metastatic pancreatic ductal adenocarcinoma […]
Momentum Newsletter: Spring 2026
This spring, progress is taking shape across every part of our work. From advancing research to expanding programs that reach more patients than ever before, we are helping hope bloom. […]
Keeping Patients Moving Forward: CancerCare’s 2025 Year-End Impact
Since 1998, the Hirshberg Foundation has partnered with CancerCare to help families navigate the financial and emotional challenges that follow a pancreatic cancer diagnosis. With your generosity, we provide bi-annual […]
